Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint 0.07 mg in Subjects With Moderate to Severe Osteoarthritis Pain of the Knee

NCT05603754 is registered in ClinicalTrials.gov with Biosplice Therapeutics, Inc. as lead sponsor.

NCT NCT05603754
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05603754 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Injection of Lorecivivint 0.07 mg in Subjects With Moderate to Severe Osteoarthritis Pain of the Knee
Lead sponsor
Biosplice Therapeutics, Inc.
Phase
Phase 3
Overall status
Completed
Start date
November 18, 2022
Completion date
February 20, 2024
Enrollment
499 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

knee osteoarthritis